Autologous haematopoietic stem-cell transplantation versus bortezomib–melphalan–prednisone, with or without bortezomib–lenalidomide–dexamethasone …

M Cavo, F Gay, M Beksac, L Pantani… - The Lancet …, 2020 - thelancet.com
Background The emergence of highly active novel agents has led some to question the role
of autologous haematopoietic stem-cell transplantation (HSCT) and subsequent …
被引用次数：320 相关文章

Autologous haematopoietic stem-cell transplantation versus bortezomib-melphalan-prednisone, with or without bortezomib-lenalidomide-dexamethasone …

M Cavo, F Gay, M Beksac, L Pantani, MT Petrucci… - The Lancet …, 2020 - sonar.ch
METHODS In this randomised, open-label, phase 3 study we recruited previously untreated
patients with multiple myeloma at 172 academic and community practice centres of the …

[引用][C] Autologous haematopoietic stem-cell transplantation versus bortezomib-melphalan-prednisone, with or without bortezomib-lenalidomide-dexamethasone …

M Cavo, F Gay, M Beksac, L Pantani, MT Petrucci… - 2020 - repository.ubn.ru.nl
Autologous haematopoietic stem-cell transplantation versus bortezomib-melphalan-prednisone,
with or without bortezomib-lenalidomide-dexamethasone consolidation therapy, and …

Autologous haematopoietic stem-cell transplantation versus bortezomib–melphalan–prednisone, with or without bortezomib–lenalidomide–dexamethasone …

M Cavo, F Gay, M Beksac, L Pantani… - THE LANCET …, 2020 - research.unipd.it
Background: The emergence of highly active novel agents has led some to question the role
of autologous haematopoietic stem-cell transplantation (HSCT) and subsequent …

Autologous haematopoietic stem-cell transplantation versus bortezomib-melphalan-prednisone, with or without bortezomib-lenalidomide-dexamethasone …

M Cavo, F Gay, M BEKSAÇ, L Pantani… - LANCET …, 2020 - avesis.ankara.edu.tr
Background The emergence of highly active novel agents has led some to question the role
of autologous haematopoietic stem-cell transplantation (HSCT) and subsequent …

Autologous haematopoietic stem-cell transplantation versus bortezomib-melphalan-prednisone, with or without bortezomib-lenalidomide-dexamethasone …

M Cavo, F Gay, M Beksac, L Pantani… - The Lancet …, 2020 - folia.unifr.ch
METHODS In this randomised, open-label, phase 3 study we recruited previously untreated
patients with multiple myeloma at 172 academic and community practice centres of the …

Autologous haematopoietic stem-cell transplantation versus bortezomib–melphalan–prednisone, with or without bortezomib–lenalidomide–dexamethasone …

M Cavo, F Gay, M Beksac, L Pantani… - THE LANCET …, 2020 - iris.unito.it
Background: The emergence of highly active novel agents has led some to question the role
of autologous haematopoietic stem-cell transplantation (HSCT) and subsequent …
[HTML] au.dk

[HTML][HTML] Autologous haematopoietic stem-cell transplantation versus bortezomib-melphalan-prednisone, with or without bortezomib-lenalidomide-dexamethasone …

M Cavo, F Gay, M Beksac, L Pantani… - The Lancet …, 2020 - pure.au.dk
Background The emergence of highly active novel agents has led some to question the role
of autologous haematopoietic stem-cell transplantation (HSCT) and subsequent …

Autologous haematopoietic stem-cell transplantation versus bortezomib–melphalan–prednisone, with or without bortezomib–lenalidomide–dexamethasone …

M Cavo, F Gay, M Beksac… - The Lancet …, 2020 - researchinformation.amsterdamumc …
Background: The emergence of highly active novel agents has led some to question the role
of autologous haematopoietic stem-cell transplantation (HSCT) and subsequent …

Autologous haematopoietic stem-cell transplantation versus bortezomib-melphalan-prednisone, with or without bortezomib-lenalidomide-dexamethasone …

M Cavo, F Gay, M Beksaç, L Pantani, M Petrucci… - Lancet …, 2020 - repub.eur.nl
Background The emergence of highly active novel agents has led some to question the role
of autologous haematopoietic stem-cell transplantation (HSCT) and subsequent …